Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis.
about
Effect of Obesity on Short- and Long-term Mortality Postcoronary Revascularization: A Meta-analysisClose relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreasComprehensive Cardiovascular Risk Reduction and Cardiac Rehabilitation in Diabetes and the Metabolic Syndrome.Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization.WRN polymorphisms affect expression levels of plasminogen activator inhibitor type 1 in cultured fibroblasts.From preadipocyte to adipocyte: differentiation-directed signals of insulin from the cell surface to the nucleus.Effects of Two Different Dietary Patterns on Inflammatory Markers, Advanced Glycation End Products and Lipids in Subjects without Type 2 Diabetes: A Randomised Crossover Study.Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin.Pleiotropic functions of plasminogen activator inhibitor-1.PAI-1 and atherothrombosis.Insulin resistance and cardiovascular disease.Epidemiological and clinical studies on insulin resistance and diabetes.Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles.The genetics of atherothrombotic disorders: a clinician's view.Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditionsDiabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategiesVirchow's triad revisited: blood constituents.PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.Gene expression in visceral and subcutaneous adipose tissues.Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia.Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents.Possibilities of intervention in intrinsic and extrinsic lysis programs.Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance.Plasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysisPlasminogen activator inhibitor-1 concentrations and bone mineral density in postmenopausal women with type 2 diabetes mellitus.Adipose tissue and atherothrombosis.A closer look at the role of urotensin II in the metabolic syndrome.Role of the fibrinolytic and matrix metalloproteinase systems in development of adipose tissue.Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysisIncreased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteriesRelevance of hemostatic risk factors on coronary morphology in patients with diabetes mellitus type 2Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndromeAssociations between homocysteine metabolism related SNPs and carotid intima-media thickness: a Chinese sib pair study.Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells.Predisposing factors to post-operative adhesion development.Thrombosis during pregnancy: Risks, prevention, and treatment for mother and fetus--harvesting the power of omic technology, biomarkers and in vitro or in vivo models to facilitate the treatment of thrombosis.A novel plasminogen activator inhibitor-1 inhibitor, TM5441, protects against high-fat diet-induced obesity and adipocyte injury in mice.Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.The role of risk factors and trigger factors in cerebrovascular events after mitral valve replacement: implications for antithrombotic management.
P2860
Q22251003-AFD4FA22-4EE4-4ED4-97C9-8D26C101934DQ24796861-CFFEAE47-ADC4-4F8B-9789-BFFFD80A7266Q30244968-CB0A5278-C6E4-47B4-A56D-7188E9EF7606Q30442725-CD02D1F3-E2A4-4EC9-890E-6B9A5EF34D58Q33321965-0F077BDA-EF91-43CA-9B40-3CB757BEFD56Q33545583-285592A9-02AB-4022-9F7C-42B404A7F4BDQ33616622-49F455A3-5042-4161-8957-5B6E2F9EB3BCQ33899837-8BA8E9B7-CC83-401B-A563-BFAD8E58EECFQ33984228-7BC505E0-3EB5-41C3-AAAF-F092768D3685Q33989347-56230857-7AFD-4BFB-896D-44E86BAD6F06Q34011027-D6867131-8AE8-45CB-886B-F61B2F058AD7Q34091890-A9CA7AF9-5475-4E00-A3BB-F199DAA69473Q34110733-DB4E3978-F34D-4FA0-A8C6-8258D6D201A3Q34215500-71C1AC90-0D9F-4729-B41A-1A84E9820A75Q34217461-572D5DCF-4136-4ABF-B650-FB0F93CBF0A4Q34245190-0249913C-4697-433B-BDA8-C4A370B350B8Q34391060-1BC405CE-5947-4FFA-B644-573A8770CAEAQ34421542-3ADB09F1-7FC1-4393-9AAF-96DE0A80D293Q34452976-369701FE-BF5E-4281-9F0B-244583BBF138Q34454561-C00BEF02-3F61-4A5A-8E12-6FF43A74E507Q34530220-E6631B38-CF51-4FAE-BDAF-290BB9791782Q34986710-30012373-8C43-4AAC-A92F-0335D78246D2Q35224521-989448C0-E1C4-4E3E-982F-B83C15247D84Q35636695-D650C3DF-3803-4BFE-9D5E-C323DE5CF18EQ35939161-72297363-23ED-4362-BCAA-FE2BA7F28243Q35945451-D03B4F13-0331-4570-AE3F-0FF3C8BB7C96Q36030434-659CB363-7083-4722-91B4-DD91D0006BD7Q36492706-2A7C282C-8212-4CB9-8B0A-2B5B5360089BQ36687953-FF8D10D7-ACED-4644-AC85-2118FDF02FC5Q37067169-21EE4661-E6CF-47E3-9525-80A71E835903Q37131350-4B857E41-0CE8-4587-8549-58BBE2AEF125Q37207656-D69F9B91-7429-4CB1-8D34-C663295AF503Q37218397-376DADD4-0C92-4C9E-BCB0-C83354BBBEF4Q37680803-81DF7BDC-74E8-4B28-AACB-1107E4AEFE4DQ38338004-61B17490-F75B-4C5F-87C8-8DBEDFAE650FQ38455443-5D58B842-B409-49C2-BCB3-33F13DD81153Q38592484-2737A3BA-6B98-451F-9168-0892238541B9Q39658243-602684D6-911E-44FD-95D4-1C2427BDEFA3Q40305997-E178D0ED-2AB9-46E9-B71D-3E4150655CCDQ41040293-4BFF58FB-E1B7-4D0C-8AD2-37D97F2DB038
P2860
Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Increased plasma plasminogen a ...... sistance and atherothrombosis.
@en
Increased plasma plasminogen a ...... sistance and atherothrombosis.
@nl
type
label
Increased plasma plasminogen a ...... sistance and atherothrombosis.
@en
Increased plasma plasminogen a ...... sistance and atherothrombosis.
@nl
prefLabel
Increased plasma plasminogen a ...... sistance and atherothrombosis.
@en
Increased plasma plasminogen a ...... sistance and atherothrombosis.
@nl
P2093
P356
P1433
P1476
Increased plasma plasminogen a ...... sistance and atherothrombosis.
@en
P2093
I Juhan-Vague
M C Alessi
P2888
P304
P356
10.1007/BF00403280
P577
1991-07-01T00:00:00Z